ZJ01, a Small Molecule Inhibitor of the Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Protein-Protein Interaction, Reduces Hyperoxic Acute Lung Injury in a Mouse Model

A 1 Jun Wan
B 1 Shaoyan Lin
D 2 Xiuling Huang
E 1 Qianqin Li
E 2 Lingjun Zeng
A 1 Songlin Du

Corresponding Author: Songlin Du, e-mail: gzdusonglin@126.com
Source of support: This study was funded by the National Natural Science Foundation of China (Grant No. 81600321) and the Science and Technology Planning Project of Guangdong Province, China (Grant No. 2017ZC0086)

Background: Hyperoxic acute lung injury (ALI) is a complication of ventilation in patients with respiratory failure. Nuclear factor erythroid-2-related factor 2 (Nrf2) has an important role in ALI. Kelch-like ECH-associated protein 1 (Keap1) binds to Nrf2. ZJ01 is a small molecule inhibitor of Keap1-Nrf2 protein-protein interaction (PPI) that can reduce Keap1-induced inhibition of Nrf2. This study aimed to investigate the effects of ZJ01 and the heme oxygenase-1 (HO-1) inhibitor, zinc protoporphyrin IX (ZnPP IX), in a mouse model of hyperoxic ALI.

Material/Methods: C57BL/6J mice included five study groups: the room air+vehicle-treated group; the room air+ZJ01 group; the hyperoxia+vehicle-treated group; the hyperoxia+ZJ01 group; and the hyperoxia+ZJ01+ZnPP IX group. ZJ01, ZnPP IX, or vehicle were given 1 h after the hyperoxia challenge. The lungs from the mice were harvested at 72 h following the hyperoxia challenge.

Results: Hyperoxia exposure for 72 h increased the activity of myeloperoxidase, the lung water content, the levels of tumor necrosis factor-α (TNF-α), and matrix metalloprotease-9 (MMP-9) in the vehicle-treated mice. ZJ01 treatment reduced hyperoxia-induced inflammation and increased the activation of Nrf2 and HO-1 compared with the vehicle-treated mice. Histology of the lungs showed that ZJ01 treatment reduced the changes of hyperoxia-induced ALI. Pretreatment with ZnPP IX reversed the beneficial effect of ZJ01.

Conclusions: ZJ01, a Keap1-Nrf2 PPI inhibitor, reduced hyperoxic ALI in a mouse model through the Nrf2/HO-1 pathway.

MeSH Keywords: Acute Lung Injury • Inflammation • NF-E2-Related Factor 1 • Oxidative Stress

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/920467
Background

Hyperoxic acute lung injury (ALI) is a complication of ventilation in patients with respiratory failure. During oxygen therapy, the generation of oxidants, including reactive oxygen species (ROS), trigger ALI and acute respiratory distress syndrome (ARDS) [1–5]. Nuclear factor erythroid 2-related factor 2 (Nrf2) has an important role in maintaining redox homeostasis by regulating the expression of antioxidants [6,7]. In a previous study, using a mouse model of ARDS, increased mortality in Nrf2-deficient mice occurred following hyperoxia [8]. The induction of Nrf2 expression has been reported to reduce the severity of ALI in studies using preclinical models and has been proposed as a potential strategy for the treatment of ALI and ARDS [6,9].

Normally, Nrf2 is inhibited by kelch-like ECH-associated protein 1 (Keap1) to control the activation of Nrf2. Keap1 inhibits Nrf2 activation through the protein-protein interaction (PPI), which results in Nrf2 ubiquitination and degradation. Therefore, disrupting the PPI of Keap1 and Nrf2 is a potential strategy to enhance Nrf2 activation and rebalance oxidants and antioxidants during ALI. Inhibitors of Keap1-Nrf2 PPI have been shown to induce Nrf2 and reduce inflammation and oxidative stress in cell and animal studies [10,11]. Recently, Lu et al. studied in vitro cell models and showed that acetaminophen-induced liver injury was reduced using an inhibitor of Keap1-Nrf2 PPI [10]. The same research group also recently investigated a mouse model and showed that the Keap1-Nrf2 PPI inhibitor, CPUY192018, reduced chronic renal inflammation [11].

ZJ01 is a novel small molecule inhibitor of Keap1-Nrf2 PPI, which has recently been shown to trigger Nrf2 nuclear translocation in H9c2 cardiac cells in vitro, resulting in increased mRNA expression levels of Nrf2 target genes, including the heme oxygenase-1 (HO-1) inhibitor gene [12]. Also, reactive oxygen species (ROS) levels were reduced by ZJ01 in vitro [12]. Therefore, this study aimed to investigate the effects of ZJ01 and the HO-1 inhibitor, zinc protoporphyrin IX (ZnPPIX), in a mouse model of hyperoxia-induced ALI.

Material and Methods

Animals and the study groups

The study protocol was reviewed and approved by the Institutional Animal Care and Use Committee of Nanfang Hospital. The animal studies were performed according to the recommendations of the Helsinki Convention for the Care and Use of Experimental Animals.
incubated with anti-Keap1 antibody (Thermo Fisher Scientific, Shanghai, China) for 10 minutes at room temperature with rotation. Immunoprecipitation was performed by incubating extracted cytosolic protein with the Dynabeads® Protein G-antibody complex in a rotating incubator at 4°C for 4 h. The complex was washed, and the target antigen was eluted. Immunoblot analysis was performed to investigate the target antigen.

Measurement of Nrf2 activity

The activity of Nrf2 was measured using a commercial TransAM™ Nrf2 kit (Active Motif, Carlsbad, CA, USA), according to the manufacturer’s instructions.

Western blot

Protein concentration was measured by a bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific, Asheville, NC, USA), according to the manufacturer’s instructions. Total protein (50 μg) underwent sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and was transferred to nitrocellulose membranes. Before incubation with specific antibodies, nonspecific binding was blocked by incubation with 5% dried skimmed milk powder. Primary antibodies used were to Nrf2, lamin B, HO-1, and β-actin (Santa Cruz Biotechnology, Dallas, TX, USA) and Keap1 (Thermo Fisher Scientific, Shanghai, China) and were incubated with the membranes at 4°C overnight. The blots were incubated with secondary horseradish
peroxidase (HRP)-conjugated anti-rabbit IgG (Santa Cruz Biotechnology, Dallas, TX, USA) for 1 h at room temperature. The bands were analyzed using ImageJ software (National Institutes of Health, Bethesda, MD, USA).

**Measurement of HO-1**

The activity of HO-1 in lung tissue samples was measured by detecting the level of bilirubin, a product of HO-1 [14]. Briefly, lung tissue supernatant was mixed with heme, NADPH, and MgCl₂ in phosphate-buffered saline (PBS) (pH 7.4) in an incubator at 37°C for 1 h. The reaction in the mixture was stopped by placing the mixture on ice. The levels of bilirubin generated in the mixture were detected using a Multiskan Sky Microplate Spectrophotometer at 530 nm (Thermo Scientific, Asheville, NC, USA).

**Analysis of glutathione peroxidase (GPx) and glutathione (GSH) levels**

The levels of GSH were measured using a kit (Cayman Chemical, Ann Arbor, USA) and the measurement of GPx activity was measured using a kit (R&D Systems, Minneapolis, MN, USA), according to the manufacturer’s instructions.

**Analysis of lipid hydroperoxide levels**

Levels of lipid hydroperoxide were measured using a commercial kit (Cayman Chemical, Ann Arbor, USA), according to the manufacturer’s instructions.

**Measurement of myeloperoxidase (MPO)**

The activity of MPO in the lung supernatant was measured using a commercial kit (Cayman Chemical, Ann Arbor, USA), according to the manufacturer’s instructions. Briefly, samples were mixed with H₂O₂, o-dianisidine hydrochloride, and PBS (pH 7.4). MPO activity was detected using a Multiskan Sky Microplate Spectrophotometer at 530 nm (Thermo Scientific, Asheville, NC, USA).

**The lung wet to dry weight (W/D) ratio**

The lung water content was detected at 72 h after hyperoxia or room air stimulation. Dried lung weight was detected at 48 h after placing the lung in an oven at 70°C.

**Measurement of tumor necrosis factor-α (TNF-α) and matrix metalloprotease-9 (MMP-9)**

TNF-α and MMP-9 levels were measured using commercial enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems Inc, Minneapolis, MN, USA), according to the manufacturer’s instructions.

**Lung histology**

Two histopathologists, who were unaware of the study groups, conducted the histological evaluation of the mouse lung tissue sections, using a scoring system for ALI, according to the American Thoracic Society [15]. In the scoring system, infiltration of neutrophils and proteinaceous debris, hyaline membranes, and septal thickening in the lung were evaluated.

**Statistical analysis**

Data were analyzed using SPSS version 20.0 software (IBM, Armonk, NY, USA). Values were expressed as the mean±standard deviation (SD). One-way analysis of variance (ANOVA) was used to compare differences between the study groups. A P-value <0.05 was considered to be statistically significant.

**Results**

**ZJ01 increased the activation of nuclear factor erythroid-2-related factor 2 (Nrf2) in the mouse model of hyperoxic acute lung injury (ALI)**

Activation of Nrf2 has previously been shown to reduce the effects of ALI [6,9]. In this study, a co-immunoprecipitation assay was performed to investigate the inhibitory effect of ZJ01, a small molecule inhibitor of Keap1-Nrf2 protein-protein interaction (PPI) that can reduce Keap1-induced inhibition of Nrf2. The results showed that ZJ01 reduced the PPI of Keap1 and Nrf2 both in lung tissues of the control and hyperoxia-stimulated mice (Figure 1B). As shown in Figure 1C and 1D, ZJ01 treatment activated Nrf2. When mice were subjected to hyperoxia, ZJ01 significantly increased the activation of Nrf2 compared with the dimethyl sulfoxide (DMSO) vehicle. In the hyperoxia-stimulated mice, ZJ01 increased heme oxygenase-1 (HO-1) activity by 3.1-fold compared with the vehicle (Figure 1E). The levels of HO-1 protein were increased by ZJ01 (Figure 2A). ZJ01 increased the activity of glutathione peroxidase (GPx) by 57% when compared with the dimethyl sulfoxide (DMSO) vehicle (Figure 2B).

**The effects of ZJ01 on glutathione (GSH) and lipid hydroperoxide**

GSH is an antioxidant. As shown in Figure 2C, the GSH level was significantly increased in the lung tissue from ZJ01-treated mice compared with mice treated with the DMSO vehicle. Oxidants cause cell damage in ALI [6,9]. The results showed that the vehicle did not inhibit the hyperoxia-induced increase in lipid hydroperoxide (Figure 2D). However, the level of lipid hydroperoxide was reduced in ZJ01-treated mice (Figure 2D).
The effects of ZJ01 on hyperoxia-induced ALI and myeloperoxidase (MPO) in the mouse model

As shown in Figure 3A, the MPO level of lung tissues was increased significantly in vehicle-treated mice exposed to hyperoxia. In contrast, the hyperoxia-induced increase in the level of MPO was inhibited by ZJ01 treatment (Figure 3A). ZJ01 also reduced hyperoxia-induced pulmonary edema (Figure 3B). As shown in Figure 3C, hyperoxia exposure significantly increased the levels of TNF-α. The levels of matrix metalloproteinase-9 (MMP-9) were increased by hyperoxia (Figure 3D). As shown in Figure 3C and 3D, these hyperoxia-induced changes were reduced by ZJ01 treatment.

The effects of ZJ01 on lung histology

Histology of the lung tissue in the mouse study groups was performed (Figures 3E, 4). Neutrophil infiltration and lung edema were found in mice that were exposed to hyperoxia for 72 h (Figure 4C). ZJ01 treatment reduced the degree of hyperoxia-induced pulmonary edema and inflammation (Figures 3E, 4D).

The effects of ZJ01 on heme oxygenase-1 (HO-1)

HO-1 is an important downstream effector of Nrf2. In this study, ZJ01 significantly increased the activity of HO-1. The mice were pretreated with the heme oxygenase-1 (HO-1) inhibitor, zinc protoporphyrin IX (ZnPP IX). As shown in Figure 5A, the ZJ01-triggered increase of HO-1 activity was significantly inhibited by ZnPP IX. Also, ZJ01-triggered reduction in the markers of inflammation and edema, including lipid hydroperoxide, MPO, the W/D ratio, and histological changes in the lung tissues, which were reversed by inhibition of HO-1 activity (Figures 4E, 5B–5D).
The aims of this study were to investigate the effects of ZJ01 and the heme oxygenase-1 (HO-1) inhibitor, zinc protoporphyrin IX (ZnPP IX), in a mouse model of hyperoxic acute lung injury (ALI). ZJ01 is a small molecule inhibitor of kelch-like ECH-associated protein 1 (Keap1) and nuclear factor erythroid-2-related factor 2 (Nrf2) protein-protein interaction (PPI) that can reduce Keap1-induced inhibition of Nrf2. Using a mouse model of ALI, the findings showed that ZJ01 reduced hyperoxia-induced histological lung changes, including neutrophil infiltration and lung edema. Also, the study findings showed that HO-1 was an effector in the effects of ZJ01 on the reduction of ALI in the mouse model.

Acute respiratory distress syndrome (ARDS) is an inflammatory disorder [1]. Activated neutrophils infiltrate the lung and the release of pro-inflammatory mediators that have a central role in ARDS [1]. The activity of myeloperoxidase (MPO) is a useful marker for the detection of neutrophil infiltration. The findings from the present study showed that the activity of MPO was inhibited by ZJ01 treatment. Also, the level of matrix metalloprotease-9 (MMP-9) in the lung was reduced in ZJ01-treated mice. MMP-9 contributes to lung injury by degrading the extracellular matrix (ECM) during the progression of ALI [16]. Activated neutrophils are a major source of MMP-9 [17]. Inhibition of neutrophil infiltration in the lung by ZJ01 may contribute to the reduction of MMP-9 to reduce tumor necrosis factor-α (TNF-α) levels in the lung. A previous study has shown that ZJ01 inhibited TNF-α in lipopolysaccharide (LPS)-stimulated H9c2 cardiac cells [12]. Another inhibitor of the Keap1-Nrf2 PPI, CPUY192018, reduced pro-inflammatory cytokines, including TNF-α, in HK-2 cells and in the kidney in mice that were stimulated by LPS [11]. The reduction of levels of TNF-α has previously been reported to be associated with reduced ALI [18].

**Discussion**

Figure 3. C57BL/6J mice were exposed to room air or hyperoxia and treated with and without ZJ01, an inhibitor of Kelch-like ECH-associated protein 1 (Keap1) protein-protein interaction (PPI). (A) Myeloperoxidase activity. (B) The ratio of wet to dry weight (W/D) of the lungs. (C) Levels of tumor necrosis factor-α (TNF-α). (D) Levels of matrix metalloprotease-9 (MMP-9). (E) Histology of the lungs. VEH, vehicle. * P<0.05 vs. the room air+VEH group; # P<0.05 vs. the hyperoxia+VEH group.
Figure 4. Histology of the lung tissue sections from C57BL/6J mice in the five study groups exposed to room air or hyperoxia and treated with and without ZJ01 and zinc protoporphyrin IX (ZnPP IX). (A) The room air+vehicle group. (B) The room air+ZJ01 group. (C) The hyperoxia+vehicle group. (D) The hyperoxia+ZJ01 group. (E) The hyperoxia+ZJ01+zinc protoporphyrin IX (ZnPP IX) group.
Figure 5. C57BL/6J mice were exposed to room air or hyperoxia and treated with and without ZJ01, an inhibitor of Kelch-like ECH-associated protein 1 (Keap1) protein-protein interaction (PPI). (A) Heme oxygenase-1 (HO-1) activity. (B) The levels of lipid hydroperoxide. (C) The activity of myeloperoxidase. (D) The ratio of wet to dry weight (W/D) of the lungs. VEH, vehicle; ZnPP IX, zinc protoporphyrin IX. * P<0.05 vs. the mice with room air+VEH treatment; # P<0.05 vs. the mice with hyperoxia+ZJ01 treatment.

ZJ01 has been previously reported to have antioxidant effects [12]. However, the effect of ZJ01 on ALI and the potential mechanisms involved have not previously been reported. Endogenous antioxidants are fundamental in host antioxidant defense mechanisms. The antioxidant effect of glutathione (GSH) has previously been reported [19]. An inhibitor of the Keap1-Nrf2 PPI has previously been shown to increase the levels of GSH levels in lipopolysaccharide (LPS)-stimulated HK-2 cells and in the kidney tissue in mice [7]. The findings from the present study showed that hyperoxia-induced reduction of GSH levels was reversed in the ZJ01-treated mouse model group.

Glutathione peroxidase (GPx) is a member of the reactive oxygen species (ROS)-scavenging enzymes. The upregulation of GPx is involved in the endogenous antioxidant capacity in several inflammatory lung diseases [20]. The findings from the present study showed that ZJ01 increased the activity of GPx. Also, the inhibition of the Keap1-Nrf2 PPI-induced increase in GPx was shown in a previous study [7]. Heme oxygenase-1 (HO-1) is an enzyme that has protective effects on the lungs during ALI [21,22]. HO-1 in modified bone marrow-derived mesenchymal stem cells reduced LPS-induced oxidative stress in cultured human pulmonary microvascular endothelial cells [23]. This study showed that HO-1 was significantly induced by ZJ01, which indicated that ZJ01 could induce antioxidants in hyperoxic ALI. Nuclear factor erythroid-2-related factor 2 (Nrf2) is a potential therapeutic target for oxidative stress, as it regulates the expression of endogenous antioxidants [6,9]. Previous studies have shown that HO-1 is induced by an inhibitor of thioredoxin reductase-1 via Nrf2-dependent mechanisms in the lung epithelium [24]. Treatment with an activator of Nrf2 has previously been shown to reduce mortality in haem-induced acute chest syndrome in a mouse model of sickle cell disease, which was reduced when HO-1 was inhibited [25]. Intestinal ischemic post-conditioning induced upregulation of Nrf2 and HO-1 expression and was protective for intestinal ischemia-reperfusion injury-induced ALI [26]. These results support the vital role that Nrf2 plays in antioxidant defense mechanisms.

In 2018, Meng et al. showed that an inhibitor of the Keap1-Nrf2 PPI activated Nrf2 in H9c2 cardiomyocytes in a lipopolysaccharide (LPS)-induced mouse myocarditis model [27]. The findings from the present study showed that ZJ01 increased Nrf2 expression in hyperoxic ALI. The changes associated with hyperoxia-induced ALI were reduced in the ZJ01-treated group. These findings support that ZJ01, a small molecule inhibitor of Keap1-Nrf2 PPI that can reduce Keap1-induced inhibition of Nrf2 and hyperoxic ALI by the induction of Nrf2. Nrf2 inhibited oxidative stress and inflammation by regulating its downstream effectors. HO-1 was an important effector in the host.
antioxidant defense mechanism in hyperoxia-induced ALI in mice following treatment with ZJ01.

Conclusions

This study aimed to investigate the effects of ZJ01, a small molecule inhibitor of Kelch-like ECH-associated protein 1 (Keap1) protein-protein interaction (PPI), and the heme oxygenase-1 (HO-1) inhibitor, zinc protoporphyrin IX (ZnPPIX), in a mouse model of hyperoxia-induced acute lung injury (ALI). ZJ01 reduced hyperoxic ALI in the mouse model through the Nrf2/HO-1 pathway.

References:

1. Sweeney RM, McAuley DF: Acute respiratory distress syndrome. Lancet, 2016; 388(10058): 2416–20
2. Cochrane CG, Spragg R, Revak SD: Pathogenesis of the adult respiratory distress syndrome. Evidence of oxidant activity in bronchoalveolar lavage fluid. J Clin Invest, 1983; 73(1): 754–61
3. Ma J, Wang Y, Wu Q et al: Seawater immersion aggravates burn-associated lung injury and inflammatory and oxidative-stress responses. Burns, 2017; 43(5): 1011–20
4. Fu C, Dai X, Yang Y et al: Dexmedetomidine attenuates lipopolysaccharide-induced acute lung injury by inhibiting oxidative stress, mitochondrial dysfunction and apoptosis in rats. Mol Med Rep, 2017; 15(1): 131–38
5. Cui H, He J, Chen H et al: Erythropoietin attenuates hyperoxia-induced lung injury by upregulating epidermal growth factor-like domain 7 in newborn rats. Biomed Rep, 2017; 6(1): 32–38
6. Liu Q, Gao Y, Ci X: Role of Nrf2 and its activators in respiratory diseases. Oxid Med Cell Longev, 2019; 2019: 7090534
7. Ma Q: Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol, 2013; 53: 401–26
8. Reddy NM, Kleeberger SR, Kessler TW et al: Disruption of Nrf2 impairs the resolution of hyperoxia-induced acute lung injury and inflammation in mice. J Immunol, 2009; 182(11): 7264–71
9. Zhao H, Eguchi S, Alam A, Ma D: The role of nuclear factor-erythroid 2 related factor 2 (Nrf2) in the protection against lung injury. Am J Physiol Lung Cell Mol Physiol, 2017; 312(2): L155–62
10. Lu MC, Zhang X, Wu F et al: Discovery of a potent Kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 (Keap1-Nrf2) protein-protein interaction inhibitor with natural proline structure as a cytoprotective agent against acetaminophen-induced hepatotoxicity. J Med Chem, 2019; 62(14): 6796–813
11. Lu MC, Zhao J, Liu YT, et al. CPY192018, a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, alleviates renal inflammation in mice by restricting oxidative stress and NF-kappaB activation. Redox Biol, 2015; 26:101266
12. Jiang CS, Zhuang CL, Zhu K et al: Identification of a novel small-molecule Keap1-Nrf2 PPI inhibitor with cytoprotective effects on LPS-induced cardiomyopathy. J Enzyme Inhib Med Chem, 2018; 33(1): 833–41
13. Xiong J, Wang K, Yuan C et al: Luteolin protects mice from severe acute pancreatitis by exerting HO-1-mediated anti-inflammatory and antioxidant effects. Int J Mol Med, 2017; 39(1): 113–25
14. Ryter SW, Kuvam E, Tyrrell RM: Heme oxygenase activity. Current methods and applications. Methods Mol Biol, 2000; 99: 369–91
15. Matute-Bello G, Downey G, Moore BB et al: An official American Thoracic Society workshop report: Features and measurements of experimental acute lung injury in animals. Am J Respir Cell Mol Biol, 2011; 44(5): 725–38
16. Qu LC, Jiao Y, Jiang ZJ et al: Acidic preconditioning protects against ischemia-reperfusion lung injury via inhibiting the expression of matrix metalloproteinase 9. J Surg Res, 2019; 235: 569–77
17. Zhang F, Hu L, Wu YX et al: Doxycycline alleviates paraprotet-induced acute lung injury by inhibiting neutrophil-derived matrix metalloproteinase 9. Int Immunopharmacol, 2019; 72: 243–51
18. Malaviya R, Laskin JD, Laskin DL: Anti-TNFalpha therapy in inflammatory lung diseases. Pharmacol Ther, 2017; 180: 90–98
19. Gould RL, Pazdro R: Impact of supplementary amino acids, micronutrients, and overall diet on glutathione homeostasis. Nutrients, 2019; 11(5): pii: E1056
20. Comhair SA, Erzurum SC: Antioxidant responses to oxidant-mediated lung diseases. Am J Physiol Lung Cell Mol Physiol, 2002; 283(2): L246–55
21. Liang Y, Fan C, Yan X et al: Berberine ameliorates lipopolysaccharide-induced acute lung injury via the PERK-mediated Nrf2/HO-1 signaling axis. Physther Res, 2019; 131(1): 130–48
22. Chi X, Guo N, Yao W et al: Induction of heme oxygenase-1 by heme protects lungs against orthotopic autologous liver transplantation-induced acute lung injury in rats. J Transl Med., 2016; 14: 35
23. Chen X, Zhang Y, Wang W et al: Mesenchymal stem cells modified with heme oxygenase-1 have enhanced paracrine function and attenuate lipopolysaccharide-induced inflammatory and oxidative damage in pulmonary microvascular endothelial cells. Cell Physiol Biochem, 2018; 49(1): 101–22
24. Dunigan K, Li Q, Li R et al: The thioredoxin reductase inhibitor auranofin induces heme oxygenase-1 in lung epithelial cells via Nrf2-dependent mechanisms. Am J Physiol Lung Cell Mol Physiol, 2018; 315(4): L545–52
25. Ghosh S, Haza R, Ilumah CA et al: Augmented Nrf2 activation protects adult sickle mice from lethal acute chest syndrome. Br J Dermatol, 2018; 176(2): 271–75
26. Meng QT, Cao C, Wu Y et al: Ischemic post-conditioning attenuates acute lung injury induced by intestinal ischemia-reperfusion in mice: Role of Nrf2. Lab Invest, 2016; 96(10): 1087–104
27. Meng N, Tang H, Zhang H et al: Fragment-growing guided design of Keap1-Nrf2 protein-protein interaction inhibitors for targeting myocarditis. Free Radic Biol Med., 2018; 117: 228–37

Acknowledgments

The authors thank ZH Deng and MZ Ling for assistance with the study.

Conflict of interest

None.